Our perspectives
in one place
Topic
Selected filters
ClearNews
See all9th Meeting of the Intergovernmental Negotiating Body (INB)
On 18 March 2024, IFPMA submitted and delivered statements at the 9th Meeting of the Intergovernmental Negotiating Body (INB). The full submitted statement is below.
Read moreDelivering equitable access in pandemics: Biopharmaceutical industry commitments
In response to the threat of future global pandemics, the biopharmaceutical industry developed a set of commitments for equitable access to essential medical countermeasures in future pandemics.
Read moreResumed session of the 7th Meeting of the Working Group on Amendments to the International Health Regulations (2005)
On 8 March 2024, IFPMA delivered a statement at the resumed session of the 7th Meeting of the Working Group on Amendments to the International Health Regulations in Geneva, where the focus of discussions was on equity.
Read moreIFPMA Statement at the closing of the WTO Ministerial Conference in Abu Dhabi
On 1 March, at the end of the 13th WTO Ministerial Conference, IFPMA issued a statement.
Read moreWTO Ministerial Conference in Abu Dhabi is an opportunity to strengthen trade and health agenda
On 23 February, ahead of the 13th WTO Ministerial Conference, IFPMA and member associations from 10 countries issued a joint statement calling on trade ministers to commit to a comprehensive trade and health agenda that will strengthen the innovation ecosystem, remove trade barriers, promote trade facilitation, strengthen regulatory systems, and address under-resourced healthcare infrastructure.
Read moreJoint Plenary Meeting of the Intergovernmental Negotiating Body (INB) and the Working Group on Amendments to the International Health Regulations (2005) (WGIHR)
On 23 February 2024, IFPMA submitted a statement at the Joint Plenary Meeting of the Intergovernmental Negotiating Body (INB) and the Working Group on the Amendments to the International Health Regulations (2005) (WGIHR) in Geneva, Switzerland.
Read morePublications
See allRegulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future
This position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.
Read moreLessons from regulatory agilities during the COVID-19 pandemic: views from members of National Regulatory Authorities
This report aims to explore the perspective of members of NRAs on the use of regulatory agilities which emerged during the COVID-19 pandemic and describe lessons learnt from this experience.
Read moreIndustry perspectives on implementation of Quality Overall Summary-Product Dossier (QOS-PD) and Quality Information Summary (QIS) for innovative medicinal products
In view of a growing complexity of product lifecycle management, industry puts forward perspectives to support the harmonization of regulatory requirements. These are intended to facilitate efficient regulatory review and approval to support timely implementation of changes and product improvements, leading to more resilient supply chains.
Read moreExpert insights
See allAccess to medicines and vaccines is about much more than price
Read moreApplying lessons learned on regulatory agility: Perspectives from national regulatory authorities
Read moreWays to strengthen the clinical research ecosystem in resource-limited settings
Read moreResources
See allOur Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read moreFebruary 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more